Navigation Links
U.S. Genomics Inc. Receives $4.5 Million Investment from BD
Date:9/23/2008

- Enters Strategic Collaboration for Development of Novel Infectious

Disease Diagnostic Platform -

WOBURN, Mass., Sept. 23 /PRNewswire/ -- U.S. Genomics today announced it has received a $4.5 million equity investment from BD (Becton, Dickinson and Company) and that the companies have entered into a strategic collaboration for development of a novel infectious disease diagnostic platform. The collaboration will focus on application of U.S. Genomics' DirectLinear Analysis(TM) technology (DLA) for the detection of a wide range of infectious organisms in a single molecular diagnostic test. A diagnostic platform based on DLA has the potential to provide information to physicians concerning pathogen identity, virulence and drug resistance within hours, as opposed to the multi-day techniques such as culturing, plating, and staining that are done today.

U.S. Genomics has invested in excess of $50 million in DLA technology, which integrates novel labeling strategies, advanced microfluidics and optical engineering to enable pathogens to be identified by rapidly analyzing individual DNA molecules present in a clinical sample. The technology is capable of simultaneously detecting a broad range of infectious organisms in a single diagnostic test. A diagnostic test based on DLA has the potential to provide clinicians and doctors' information important for patient health, such as which drugs a specific pathogen may be resistant to, and which drugs could be used for most effective patient treatment.

"We are very pleased to enter into this strategic relationship with BD," said John J. Canepa, U.S. Genomics' CEO. "BD is the clear market leader in clinical microbiology and their deep experience in product development is an ideal complement to our innovative DLA technology and strong research team. We share the goal of establishing a new, faster, more accurate capability for microbial diagnostics, based on genotype, leading to more effective patient treatment and better outcomes."

DLA technology, developed with support from venture capital investors, NSF, DARPA, and the U.S. Department of Homeland Security (DHS), also has the potential to be applied in applications such as patient screening, hospital monitoring, epidemiology and forensics. U.S. Genomics currently has an extremely sensitive and accurate sensor for detection of biological threats in development under the DHS Bioagent Autonomous Network Detector program. Similar precision is required in hospital settings, where regulations may restrict reimbursement for costs associated with certain infections that occur as a result of hospital procedures. DLA has the potential to rapidly and accurately resolve whether a patient who became sick during a hospital stay was infected with a known hospital-based organism, or a strain not previously seen.

"We see tremendous potential for application of DLA technology," Canepa continued. "Working closely with BD on this collaboration, we plan to prioritize development efforts toward the multi-billion dollar infectious disease testing market. Further, the flexibility of the DLA technology to address a wide range of sample types creates future opportunities for U.S. Genomics to expand into significant new application areas, such as bio- security, bio-surveillance, and environmental and food safety testing."

About U.S. Genomics, Inc.

U.S. Genomics is pioneering single molecule biology technologies for diagnostics and biodefense applications by combining advanced microfluidics, optical engineering, and novel labeling strategies. Using its DNA mapping technology, the Company is developing sophisticated biological sensors for the detection and identification of pathogens and biomarkers in the air and other biologically relevant materials. The Company's biodefense focus on airborne pathogens has been funded in part by contracts from the U.S. Department of Homeland Security Science and Technology Directorate. U.S. Genomics' portfolio of products will further a greater understanding of genetics and disease pathways leading to more effective use of therapeutics, and a range of diagnostics, and biodefense applications. For more information, please visit http://www.usgenomics.com


'/>"/>
SOURCE U.S. Genomics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):